Visit Pii at CPhI north america® and stop by Booth 2009, May 17 - 19 at the Pennsylvania Convention Center, PHL.
Book a meeting on our calendar link below to schedule and connect with one of Pii's CPhI north america® show participants.
Connect with John Fowler,
Our President and CEO
John Fowler joined Pii on March 7th, 2022. He is a seasoned veteran with more than 30 years of experience in the pharmaceutical and chemical industries. John believes Pii has a great business model and is uniquely qualified to help its customers solve complex development challenges while accelerating time to market.
Connect with Luis Molina,
Director of Business Management
Luis started at Pii in 2021 and oversees key account management, change orders, and supports the execution of commercial deliveries and technology transfers. He works closely with Pii’s Supply Chain and Operations team to deliver on-time-in-full (OTIF) and right first time (RFT) for Pii's customers.
Connect with Barbara Holland,
Business Development Associate
Barbara Holland returns to Pii as a Business Development Director, bringing with her extensive knowledge about early-stage formulation and development through commercialization. Barbara previously worked at Pii for twelve years, serving in a variety of roles.
Pii's 25+ years of CDMO services
Learn about Pii's 25+ years of CDMO services inclusive of managing and executing the development of parenteral and oral formulations for your drug candidate. We assist with your drug concept, research and development, clinical, scale-up/ tech transfer and commercialization. Our agility, expertise, and the highest quality of service will get your product to market fast.
Pii offers Parenteral Drug Formulation, Process Development and Fill-finish services. Our proven capabilities include:
• Aseptic filling
• Potent (HPAPI) up to SafeBridge® Category IV
• Cytotoxic drugs into vials, syringes, and cartridges
• Lyophilization of biologic NCE
• Terminal sterilization
• Small molecule
Vial Sizes from 3 mL to 50 mL using Millrock lyophilization technology provide critical synergies between the development lab and manufacturing line, ensuring your outcomes are met with the highest quality and always on time.
Our range of oral dose delivery options includes complex soft gel production, gives your drug excellent solubility and stability, delivering the right dosage at the right time in the patient’s body. Our proven capabilities include:
• Highly potent compounds (including Safebridge Category IV and Hormones)
• DEA controlled substances (schedule I-V, L1)
• Combination of multiple APIs
• Pre-formulation to Phase III studies
• Bioavailability enhancement
• Modified and controlled-release tablets
• Capsules and suspensions
• Formulation of complex drug products